Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL

Affiliations

• ¹ Mie University, Tsu, Japan.
• ² Kanagawa Cancer Center, Yokohama, Japan.
• ³ Kanazawa University, Kanazawa, Japan.
• ⁴ Toranomon Hospital, Tokyo, Japan.
• ⁵ Gunma Cancer Center, Ohta, Japan.
• ⁶ Kyoto University, Kyoto, Japan.
• ⁷ Okayama Medical Center, Okayama, Japan.
• ⁸ Shikoku Cancer Center, Matsuyama, Japan.
• ⁹ Kainan Hospital, Yatomi, Japan.
• ¹⁰ Saitama Medical University, Hidaka, Japan.
• ¹¹ Fujita Medical University, Toyoake, Japan.
• ¹² Keiju Medical Center, Kanazawa, Japan.
• ¹³ Fukui-ken Saiseikai Hospital, Fukui, Japan.
• ¹⁴ Kyushu Cancer Center, Fukuoka, Japan.
• ¹⁵ Tohoku University, Sendai, Japan.
• ¹⁶ Toranomon Hospital Kajigaya, Kajigaya, Japan.
• ¹⁷ St. Marianna University, Kawasaki, Japan.
• ¹⁸ Kanazawa Medical University, Ishikawa, Japan.
• ¹⁹ Fujioka General Hospital, Fujioka, Japan.
• ²⁰ Tokyo Medical Center, Tokyo, Japan.
• ²¹ Shinko Hospital, Kobe, Japan.
• ²² University of Tsukuba, Tsukuba, Japan.
• ²³ Yokohama City University, Yokohama, Japan.
• ²⁴ Osaka University, Suita, Japan.
• ²⁵ Shinshu Medical Center, Suzaka, Japan.
• ²⁶ Kyushu University, Fukuoka, Japan.
• ²⁷ National Cancer Center Hospital, Tokyo, Japan.
• ²⁸ Aichi Cancer Center Hospital, Nagoya, Japan.
• ²⁹ Shimane University, Izumo, Japan.
• ³⁰ Kurume University, Kurume, Japan.